SCORR Marketing

High costs and recruitment issues drive the globalization of clinical trials

Monday, August 21, 2017

The pursuit of global trials is increasing. A report by SCORR Marketing and Applied Clinical Trials examined the reasons why companies are pursuing global clinical trials and the challenges they face in conducting them. The top two reasons cited in the survey for trials exiting the U.S. and Western Europe and moving to other regions were high costs and  patient recruitment difficulty.

[Read More]

Survey: Clinical trials changing dramatically

Friday, June 23, 2017

SCORR Marketing, a global health science marketing and communications firm, has announced that a new survey report, Clinical Trials: Past, Present and Future, is now available for free download. The report, produced in partnership with Applied Clinical Trials, describes what clinical trial professionals perceive to be the biggest changes in clinical trials in the last 10 years and what they expect as they continue to evolve in the future.

[Read More]

SCORR Marketing adds three to team

Friday, June 16, 2017

SCORR Marketing, a global health science marketing and communications firm, announced the addition of three employees with health science marketing expertise, including Lea LaFerla, vice president of marketing services; Edlyn Tobias, marketing technology manager; and James Wang, associate director of business development.

[Read More]

Bridging Clinical Research and Clinical Health Care Collaborative to launch

Wednesday, June 14, 2017

In 2018, the Bridging Clinical Research and Clinical Health Care Collaborative will bring together industry leaders from pharma, biotech, CROs, healthcare organizations, advocacy groups and the FDA to advance the participation of patients and physicians in the conduct of clinical trials. The conference will be April 4–5, 2018, at the Gaylord National Resort and Conference Center in National Harbor, Maryland.

[Read More]

Big Data in clinical trials: Promise and pitfalls

Monday, August 15, 2016

Privacy versus medical progress. Proprietary ownership versus public information. Cost-effectiveness versus unnecessary burdens. Welcome to the swirl of opinions and emotions around Big Data and its potential—or not—in the clinical trials industry.

[Read More]